Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases
Vascular adhesion protein-1 (VAP-1) is a semicarbazide-sensitive amine oxidase (SSAO), whose enzymatic activity regulates the adhesion/exudation of leukocytes in/from blood vessels. Due to its abundant expressions in vascular systems and prominent roles in inflammations, increasing attentions have b...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2021-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a4a39e96bfbc45d58e9e58f3e018e903 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Hui Li |e author |
| 700 | 1 | 0 | |a Shiyu Du |e author |
| 700 | 1 | 0 | |a Panpan Niu |e author |
| 700 | 1 | 0 | |a Xiaosong Gu |e author |
| 700 | 1 | 0 | |a Jun Wang |e author |
| 700 | 1 | 0 | |a Ying Zhao |e author |
| 245 | 0 | 0 | |a Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases |
| 260 | |b Frontiers Media S.A., |c 2021-07-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2021.679707 | ||
| 520 | |a Vascular adhesion protein-1 (VAP-1) is a semicarbazide-sensitive amine oxidase (SSAO), whose enzymatic activity regulates the adhesion/exudation of leukocytes in/from blood vessels. Due to its abundant expressions in vascular systems and prominent roles in inflammations, increasing attentions have been paid to the roles of VAP-1/SSAO in atherosclerosis, a chronic vascular inflammation that eventually drives clinical cardiovascular events. Clinical studies have demonstrated a potential value of soluble VAP-1 (sVAP-1) for the diagnosis and prognosis of cardiovascular diseases. Recent findings revealed that VAP-1 is expressed in atherosclerotic plaques and treatment with VAP-1 inhibitors alleviates the progression of atherosclerosis. This review will focus on the roles of VAP-1/SSAO in the progression of atherosclerotic lesions and therapeutic potentials of VAP-1 inhibitors for cardiovascular diseases. | ||
| 546 | |a EN | ||
| 690 | |a VAP-1 | ||
| 690 | |a inflammation | ||
| 690 | |a atherosclerosis | ||
| 690 | |a myocardial infarction | ||
| 690 | |a stroke | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 12 (2021) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2021.679707/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a4a39e96bfbc45d58e9e58f3e018e903 |z Connect to this object online. |